GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials | Synapse
July 10, 2019Open Access
GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials
Key Points
Key points are not available for this paper at this time.
Abstract
With large enough sample sizes, GFR slope may be a viable surrogate for clinical end points in CKD RCTs.